You are here: Industry Insights > gilead

News List

Pfizer signs multi-year deal to manufacture Gilead’s remdesivir pharmaceutical-technology
August 11, 2020
Pfizer has entered into a multi-year agreement to manufacture and supply Gilead Science’s experimental antiviral drug remdesivir, for the treatment of Covid-19 patients.
Pfizer signs agreement with Gilead Sciences to manufacture remdesivir expresspharma
August 10, 2020
Pfizer will provide contract manufacturing services through its McPherson, Kansas plant.
Health Canada authorises remdesivir as first Covid-19 treatment pharmaceutical-technology
July 30, 2020
Health Canada has granted conditional approval to Gilead Sciences’ remdesivir (Veklury) to treat patients with severe Covid-19 who have pneumonia and need oxygen support.
Gilead to acquire stake in Tizona Therapeutics for $300n pharmaceutical-technology
July 23, 2020
Gilead Sciences is set to acquire a 49.9% equity interest in cancer immunotherapies maker Tizona Therapeutics through an investment of $300m.
Inhaled formulation of remdesivir enters clinical trials europeanpharmaceuticalreview
July 14, 2020
Gilead reveals the novel inhaled formulation of remdesivir entered Phase I trials to establish if it could be used to treat mild to moderate COVID-19.
Gilead says remdesivir reduced risk of death in Covid-19 patients, more studies needed expresspharma
July 13, 2020
The company, which had initially released the data from the trial in April, said the finding requires confirmation in clinical trials.
Gilead begins PhI trial of inhaled remdesivir pharmatimes
July 10, 2020
Gilead has begun testing an inhalable version of remdesivir in a Phase Ia study, to assess its potential as a treatment for COVID-19.
Gilead begins testing inhalable form of remdesivir for COVID-19 expresspharma
July 10, 2020
The company said the trial will test the drug particularly in those cases where the disease has not progressed to require hospitalization.
Gilead gets EC conditional approval for remdesivir to treat Covid-19 pharmaceutical-technology
July 07, 2020
The European Commission (EC) has provided conditional marketing authorisation for Gilead Sciences to use Veklury (remdesivir) for the treatment of Covid-19.
Gilead prices COVID-19 drug remdesivir at $2,340 per patient in developed nations expresspharma
July 01, 2020
Remdesivir is expected to be in high demand as one of the only treatments so far shown to alter the course of COVID-19.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 21 22 Next page